

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-100075-PIP01-21

Scope of the Application

Active Substance(s)

leniolisib

Condition(s)

Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Pharmaceutical Form(s)

Film-coated tablet; Capsule, hard; Granules

Route(s) of Administration

Oral use

Name / Corporate name of the PIP applicant

Pharming Group N.V.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Pharming Group N.V. submitted to the licensing authority on 29/03/2021 13:31 BST an application for a Paediatric Investigation Plan

The procedure started on 09/06/2021 08:52 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

Final Decision Letter

MHRA-100075-PIP01-21

Of 18/03/2022 16:22 GMT

On the adopted decision for leniolisib (MHRA-100075-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for leniolisib, Film-coated tablet; Capsule, hard; Granules , Oral use .

This decision is addressed to Pharming Group N.V., Darwinweg 24, Leiden, Netherlands, 2333 CR

ANNEX I

1. Waiver

1.1 Condition:

Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age. Pharmaceutical form(s): Film-coated tablet; Capsule, hard; Granules Route(s) of administration: Oral use Reason for granting waiver: on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of activated phosphoinositide 3-kinase delta (#) syndrome (APDS)

2.2 Indication(s) targeted by the PIP:

Treatment of activated phosphoinositide 3-kinase delta (#) syndrome (APDS)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 year to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet; Capsule, hard; Granules

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 (PIPLform) Development of an oral age-appropriate formulation.
Non-Clinical Studies	0	Not applicable
Clinical Studies	5	Study 2 (CCDZ173X2201 -part II) Double-blind, randomised, assessor-blind, placebo-controlled trial to evaluate safety and efficacy of leniolisib compared to placebo in children from 12 years to less than 18 years of age (and adults) with documented activated phosphoinositide 3-kinase delta syndrome (APDS). Study 3 (CCDZ173X2201 - part I) Open label, single arm, dose-finding trial to evaluate pharmacokinetics, safety, activity of leniolisib in children from 12 years to less than 18 years of age (and adults) with documented APDS. Study 4 (CCDZ173X2201E1) Open-label, long term safety and tolerability trial of leniolisib in children from 12 years to less than 18 years of age (and adults) who participated in study CCDZ173X2201 part I or II. Study 5 (PIPCL1) Open-label, single arm, two part trial to evaluate pharmacokinetics, safety and efficacy of leniolisib in children from 4 years to less than 12 years of age with documented APDS. Study 6 (PIPCL2) Open-label, single arm, two part trial to evaluate pharmacokinetics, safety and efficacy of leniolisib in children from 1 year

		to less than 7 years of age with documented APDS.
Extrapolation, Modeling & Simulation Studies	1	Study 7 (PIPLMS) Modelling and simulation study to support the use of leniolisib in paediatric patients from 1 year to less than 18 years of age with documented APDS.
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/09/2026
Deferral of one or more studies contained in the paediatric investigation plan:	Yes